High-Flow Nasal Oxygen in Early Home Pulmonary Rehabilitation for Exertional Hypoxaemia: A Pilot Randomised Feasibility Trial.

RespirologyJul 3, 2026 (epub)
Clinical ResearchPulmonology

Yingjuan Mok, Jing Wen Foong, Hang Siang Wong et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized feasibility trial evaluated the integration of high-flow nasal oxygen (HFO) in an early home-based pulmonary rehabilitation (PR) program for patients with exertional hypoxaemia (EH) post-hospitalization. Among 56 patients, 52 completed follow-up at 4 weeks. The HFO-PR group showed lower adherence to self-directed sessions compared to the PR-only group, with completion rates of 60% and 89%, respectively.

Key findings

  • Overall PR program acceptance was 67% and uptake was 62%.
  • Completion rates were 60% for HFO-PR and 89% for PR-only.
  • In COPD patients, the 1-min sit-to-stand test improved by 4.6 repetitions in the HFO group and 5.3 in the PR-only group.

Why it matters

Understanding the feasibility of home-based PR with HFO for patients with exertional hypoxaemia can inform future rehabilitation strategies, particularly in enhancing adherence and optimizing patient outcomes post-discharge.

Source

PubMed · PMID 42397015

Published in Respirology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.